Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.64 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.45 |
| ▸ | FEN1 | P39748 | 2/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31003508 | 0.79 | ADORA2A (0.50) | ADORA2AALOX5APFEN1TP53MAPK1 | |
| SCHEMBL4322580 | 0.73 | NCF1 (0.75) | — | |
| SCHEMBL29418129 | 0.72 | TP53 (0.69) | TP53MAPK1RAB9A | |
| SCHEMBL159005 | 0.72 | TP53 (0.69) | TP53MAPK1RAB9A | |
| SCHEMBL1938309 | 0.72 | TP53 (0.57) | ALOX5APFEN1TP53MAPK1RAB9A | |
| SCHEMBL16863977 | 0.71 | DCPS (0.63) | DHFR | |
| SCHEMBL421987 | 0.70 | ADORA2A (1.00) | ADORA2ANUDT1SCN9A | |
| SCHEMBL27310325 | 0.70 | ADORA2A (1.00) | ADORA2ANUDT1DHFR | |
| SCHEMBL7645459 | 0.70 | HTR1B (0.54) | TP53MAPK1RAB9A | |
| SCHEMBL16614075 | 0.70 | ADORA2A (0.70) | ADORA2ANUDT1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | claimed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | ADORA2A 1163/4885NUDT1 1078/4885SCN9A 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.